Century Therapeutics(NASDAQ) IPSC

Century Therapeutics, Inc. develops off-the-shelf cell therapies to treat people with cancer and autoimmune diseases. These treatments use healthy donor cells so patients do not have to wait for personalized medicine. The company aims to make advanced healthcare faster and more accessible for everyone.

Fighting Disease With New Cells

• Islet Cell Therapy: Lead program CNTY-813 replaces insulin-producing cells in patients with type 1 diabetes.
• T Cell Therapy: Engineered immune cells like CNTY-308 target B-cell cancers and autoimmune diseases.
• NK Cell Therapy: Programs like CNTY-101 use natural killer cells to attack solid tumors and blood cancers.
• Allo-Evasion Technology: Genetic editing platform designed to prevent the patient's immune system from rejecting donor cells.

Partnerships and Growth Moves

• Established multiple licenses with Fujifilm Cellular Dynamics, Inc. starting in September 2018 to access stem cell technology.
• Partnered with Bristol-Myers Squibb in Jan. 7, 2022 to develop blood cancer therapies.
• Acquired Clade Therapeutics in 2024 to expand its research pipeline and cell line access.
• Terminated the major collaboration with Bristol-Myers Squibb in March 2025 following a partner portfolio review.
• Closed a $135 million private placement in January 2026 to fund clinical development.

What Makes the Platform Different?

Century Therapeutics uses induced pluripotent stem cells that can turn into any cell type. This allows the company to produce unlimited, genetically consistent treatments without needing new donor samples for every patient.

Key Financial Results

• Cash, cash equivalents, and investments totaled $197.2 million as of June 30, 2026.
• Net loss was $56.2 million for the six-month period ended June 30, 2026.
• Collaboration revenue was zero for the six-month period ended June 30, 2026.
• Research and development costs fell to $36.7 million for the six-month period ended June 30, 2026.
• The company reported an accumulated deficit of $848.1 million as of June 30, 2026.

Bottom Line

Century Therapeutics has moved from early research partnerships to advancing its own pipeline of engineered stem cell therapies. The company maintains a significant cash position to support its clinical programs through early 2029.